Every member of the Huntington’s disease community — patients, their family members, friends, and supporters — plays a crucial…
Articles by Lindsey Shapiro, PhD
Huntington’s Disease Society of America (HDSA) leaders at the group’s 41st annual convention unveiled a new strategic plan and…
UniQure plans to ask the U.S Food and Drug Administration (FDA) for accelerated approval of AMT-130 to treat…
A postdoctoral researcher at the University of Michigan won a three-year grant to support her work investigating the cellular mechanisms…
Daily treatment with Ingrezza (valbenazine) led to reductions in motor- and cognitive-related disease burden for adults with chorea due…
uniQure plans to submit a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) early next year…
Daily treatment with Ingrezza (valbenazine) eases the jerky, involuntary movements known as chorea across different body regions in…
One-year results from the Phase 2 PIVOT-HD clinical trial testing PTC Therapeutics’ Huntington’s disease treatment PTC518 are expected in…
While the vast majority of Huntington’s disease patients in North America have the uncontrolled and jerky movements known as…
Atalanta Therapeutics has raised $97 million to support planned Phase 1 clinical trials of its experimental RNA interference…